Author name: Kristen Hartman

Targeted Toxins for Neuroscience Antibody Screening for Neuroscience There is a growing need for therapeutics for cancer, autoimmune diseases, blood diseases and Alzheimer’s disease. Due to their ability to bind to a specific target antigen, monoclonal antibodies are increasingly being screened for therapeutic drug development. In May 2021, the FDA approved the 100th monoclonal antibody

One of the more common methods of using Streptavidin-ZAP is to couple the complex with biotinylated antibodies. However, there are also many instances of biotinylated ligands, peptides, and even biotinylated major histocompatibility complex (MHC) tetramers in immunology fields. B-Cell Targeting. An example of utilizing Streptavidin-ZAP to study ligands that target CD22 were shown by Collins

NGFr (ME20.4, p75) Mouse Monoclonal (Cat. #AB-N07) The p75 neurotrophin receptor (p75NTR), also known as the low affinity nerve growth factor receptor, binds nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4 with varying specificities. The p75NTR plays an important role in neurotrophic factor signaling and has been shown to modulate the susceptibility of selective